Cargando…

Targeting Myotonic Dystrophy Type 1 with Metformin

Myotonic dystrophy type 1 (DM1) is a multisystemic disorder of genetic origin. Progressive muscular weakness, atrophy and myotonia are its most prominent neuromuscular features, while additional clinical manifestations in multiple organs are also common. Overall, DM1 features resemble accelerated ag...

Descripción completa

Detalles Bibliográficos
Autores principales:	García-Puga, Mikel, Saenz-Antoñanzas, Ander, Matheu, Ander, López de Munain, Adolfo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8910924/ https://www.ncbi.nlm.nih.gov/pubmed/35270043 http://dx.doi.org/10.3390/ijms23052901

Ejemplares similares

Myotonic Dystrophy type 1 cells display impaired metabolism and mitochondrial dysfunction that are reversed by metformin
por: García-Puga, Mikel, et al.
Publicado: (2020)

Senescence plays a role in myotonic dystrophy type 1
por: García-Puga, Mikel, et al.
Publicado: (2022)

Muscle wasting in myotonic dystrophies: a model of premature aging
por: Mateos-Aierdi, Alba Judith, et al.
Publicado: (2015)

Leukocyte telomere length in patients with myotonic dystrophy type I: a pilot study
por: Wang, Youjin, et al.
Publicado: (2019)

Social cognition in myotonic dystrophy type 1: Specific or secondary impairment?
por: Labayru, Garazi, et al.
Publicado: (2018)

Towards precision medicine: linking genetic and cellular heterogeneity in gastric cancer
por: Carrasco-Garcia, Estefania, et al.
Publicado: (2018)

Age‐related cognitive decline in myotonic dystrophy type 1: An 11‐year longitudinal follow‐up study
por: Labayru, Garazi, et al.
Publicado: (2019)

SOX9 promotes tumor progression through the axis BMI1-p21(CIP)
por: Aldaz, Paula, et al.
Publicado: (2020)

Six Serum miRNAs Fail to Validate as Myotonic Dystrophy Type 1 Biomarkers
por: Fernandez-Costa, Juan M., et al.
Publicado: (2016)

Regional brain atrophy in gray and white matter is associated with cognitive impairment in Myotonic Dystrophy type 1
por: Labayru, Garazi, et al.
Publicado: (2019)

Relevance of oxidative stress and inflammation in frailty based on human studies and mouse models
por: Álvarez-Satta, María, et al.
Publicado: (2020)

Shedding light on motor premanifest myotonic dystrophy type 1: A molecular, muscular and central nervous system follow‐up study
por: Garmendia, Joana, et al.
Publicado: (2022)

Transcriptional signatures of synaptic vesicle genes define myotonic dystrophy type I neurodegeneration
por: Jimenez‐Marin, Antonio, et al.
Publicado: (2021)

Cardiac Pathology in Myotonic Dystrophy Type 1
por: Mahadevan, Mani S., et al.
Publicado: (2021)

Chaperone-Mediated Autophagy Controls Proteomic and Transcriptomic Pathways to Maintain Glioma Stem Cell Activity
por: Auzmendi-Iriarte, Jaione, et al.
Publicado: (2022)

Liquid Biopsy in Glioblastoma: Opportunities, Applications and Challenges
por: Saenz-Antoñanzas, Ander, et al.
Publicado: (2019)

Myotonic dystrophy
por: Patterson, VH
Publicado: (1990)

Delay of EGF-Stimulated EGFR Degradation in Myotonic Dystrophy Type 1 (DM1)
por: Alegre-Cortés, Eva, et al.
Publicado: (2022)

CRISPR/Cas9 Deletion of SOX2 Regulatory Region 2 (SRR2) Decreases SOX2 Malignant Activity in Glioblastoma
por: Saenz-Antoñanzas, Ander, et al.
Publicado: (2021)

Cancer and Myotonic Dystrophy
por: D’Ambrosio, Eleonora S., et al.
Publicado: (2023)

CD8(+) T cells are increased in the subventricular zone with physiological and pathological aging
por: Moreno‐Valladares, Manuel, et al.
Publicado: (2020)

CD8(+) T cells are present at low levels in the white matter with physiological and pathological aging
por: Moreno-Valladares, Manuel, et al.
Publicado: (2020)

A new approach based on targeted pooled DNA sequencing identifies novel mutations in patients with Inherited Retinal Dystrophies
por: Ezquerra-Inchausti, Maitane, et al.
Publicado: (2018)

Metabolic Alterations in Myotonic Dystrophy Type 1 and Their Correlation with Lipin
por: Mateus, Tiago, et al.
Publicado: (2021)

Application of Antisense Conjugates for the Treatment of Myotonic Dystrophy Type 1
por: Stoodley, Jessica, et al.
Publicado: (2023)

Development of Therapeutic Approaches for Myotonic Dystrophies Type 1 and Type 2
por: Timchenko, Lubov
Publicado: (2022)

The Biomarker Potential of miRNAs in Myotonic Dystrophy Type I
por: Koehorst, Emma, et al.
Publicado: (2020)

Author Correction: A new approach based on targeted pooled DNA sequencing identifies novel mutations in patients with Inherited Retinal Dystrophies
por: Ezquerra-Inchausti, Maitane, et al.
Publicado: (2019)

Disease burden of myotonic dystrophy type 1
por: Landfeldt, Erik, et al.
Publicado: (2019)

Targeting mTOR as a Therapeutic Approach in Medulloblastoma
por: Aldaregia, Juncal, et al.
Publicado: (2018)

An Overview of Alternative Splicing Defects Implicated in Myotonic Dystrophy Type I
por: López-Martínez, Andrea, et al.
Publicado: (2020)

Molecular Genetics and Genetic Testing in Myotonic Dystrophy Type 1
por: Savić Pavićević, Dušanka, et al.
Publicado: (2013)

Consensus-based care recommendations for adults with myotonic dystrophy type 1
por: Ashizawa, Tetsuo, et al.
Publicado: (2018)

Modeling Myotonic Dystrophy Type 2 Using Drosophila melanogaster
por: Marzullo, Marta, et al.
Publicado: (2023)

Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy
por: Cerro-Herreros, Estefanía, et al.
Publicado: (2021)

Fuchs' Endothelial Corneal Dystrophy in Patients With Myotonic Dystrophy, Type 1
por: Winkler, Nelson S., et al.
Publicado: (2018)

Molecular and Clinical Implications of Variant Repeats in Myotonic Dystrophy Type 1
por: Peric, Stojan, et al.
Publicado: (2021)

TNNT2 Missplicing in Skeletal Muscle as a Cardiac Biomarker in Myotonic Dystrophy Type 1 but Not in Myotonic Dystrophy Type 2
por: Bosè, Francesca, et al.
Publicado: (2019)

Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma
por: Auzmendi-Iriarte, Jaione, et al.
Publicado: (2020)

Marathoning with myotonic dystrophy type 2 (proximal myotonic myopathy) and leukopenia
por: Finsterer, Josef, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_tjt5ukcc9faq7aeopnvte1v4eg